)
Assertio (ASRT) investor relations material
Assertio Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Leadership transition in October 2025 renewed focus on leveraging Rolvedon as the core growth driver and optimizing commercial operations.
FY2025 net product sales and adjusted EBITDA exceeded guidance, driven by strong performance in core assets and disciplined capital allocation.
Strategic shift away from broad specialty product acquisitions toward selective, high-return oncology assets and leveraging existing commercial capabilities.
Commercial infrastructure is robust, scalable, and focused on community oncology clinics, supporting future product launches.
Financial highlights
FY2025 net product sales reached $117.1M, slightly down from $120.8M in 2024, with Rolvedon sales up to $68.2M and Sympazan sales up to $11.3M year-over-year.
Q4 2025 total product sales were $12.8M, down from $29.6M year-over-year, due to Rolvedon channel inventory timing.
Gross margin improved to 70% in 2025 from 68% in 2024; Q4 gross margin was 75%.
Adjusted EBITDA for FY2025 was $22.7M, up from $18.3M in 2024; Q4 adjusted EBITDA was -$4.1M.
Cash and equivalents at year-end were $63.4M, down from $100.1M at year-end 2024, reflecting working capital changes and divestment outflows.
Outlook and guidance
FY2026 net product sales expected between $110M–$125M and adjusted EBITDA between $28M–$40M.
Rolvedon expected to drive growth, offsetting declines in legacy assets; normalized sales pattern anticipated from Q2 2026.
No expected channel inventory build in 2026; shipments to align with demand.
Indocin sales expected to decline due to increased generic competition.
Rolvedon sales under new label anticipated to begin in Q2 2026, with continued leadership in Medicare Part B clinic market share.
- ROLVEDON growth offset Indocin decline; sales $30.7M, net loss $3.7M, cash $88.4M.ASRT
Q2 20242 Feb 2026 - Rolvedon drives growth with $60M–$100M potential, supported by strong cash flow and new leadership.ASRT
Small-Cap Growth Virtual Investor Conference1 Feb 2026 - Rolvedon drives growth as expansion and clinical initiatives position for long-term value.ASRT
Maxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026 - Q3 sales were $28.7M as Indocin fell, Rolvedon held steady, and margins improved.ASRT
Q3 202415 Jan 2026 - Rolvedon growth offsets Indocin decline; 2025 targets $108–$123M sales, $10–$19M EBITDA.ASRT
Q4 202426 Dec 2025 - Proxy seeks approval for director elections, equity plan expansion, reverse split, and auditor ratification.ASRT
Proxy Filing2 Dec 2025 - Proxy seeks approval for director elections, equity plan expansion, reverse split, and auditor ratification.ASRT
Proxy Filing2 Dec 2025 - Transformation phase prioritizes Rolvedon, Sympazan, and M&A for future growth.ASRT
Alliance Global Partners Healthcare Company Showcase26 Nov 2025 - Q1 2025 sales met guidance; net loss widened; legal risks reduced; growth focus maintained.ASRT
Q1 202524 Nov 2025
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)